CT · State regulatory reference

Connecticut.

Restrictive

Connecticut is restrictive on the enforcement axis: in 2025 Attorney General William Tong opened a documented crackdown on bootleg GLP-1s — a CUTPA lawsuit against distributor Triggered Brand (May 2025) over 'research grade' semaglutide/tirzepatide, followed by cease-and-desist letters to med spas and a settlement (December 2025). Telehealth practice under Conn. Gen. Stat. § 19a-906 permits establishing care and prescribing non-controlled drugs (including GLP-1s) via telehealth without a prior in-person visit, and compounding follows USP <795>/<797> under the Commission of Pharmacy with no CT-specific GLP-1 rule beyond federal 503A. The enforcement targets illegal research-grade product, not compliant physician-supervised therapy.

Last reviewed · 2026-05-25 · verified entry

Agencies

Medical board

Connecticut Medical Board

https://portal.ct.gov/DPH/Practitioner-Licensing--Investigations/Medical/Medical-Board ↗

Pharmacy board

Connecticut Board of Pharmacy

https://portal.ct.gov/DCP/Drug-Control-Division/Drug-Control/Connecticut-Commission-of-Pharmacy ↗

TPC notes

Telehealth

Under Conn. Gen. Stat. § 19a-906, an initial visit and prescribing may occur via synchronous audio-video (audio-only under specified conditions) with no mandatory prior in-person exam; telehealth providers may not prescribe most Schedule II/III controlled substances. GLP-1s and peptides are non-controlled, so telehealth prescribing of them is not restricted.

Compounding

Connecticut enforces USP <795>/<797> via the Commission of Pharmacy / Drug Control Division with no state-specific GLP-1 rule beyond federal 503A; the distinctive signal is AG enforcement against research-grade/bootleg GLP-1 distributors and med spas, not a compounding regulation.

Sources